Table 3.
Treatment and outcome
| Characteristic | n/Na (%) | Characteristic | n/Na (%) |
|---|---|---|---|
| No treatment | 99/655 (15) | Other treatment modalities | |
| First line therapy | 434/539 (81) | Neurosurgical intervention | 30/230 (13) |
| Second line therapy | 144/539 (27) | Anti-epileptic medication | 14/106 (13) |
| Third line therapy | 49/539 (9) | Hormonal substitution | 18/227 (8) |
| Overall treatment | Follow-up, yr., mean (SD) | 4.4 (SD 3.15) | |
| Corticosteroids | 546/655 (83) | Outcome | |
| Methotrexate | 105/655 (16) | Remission | 126/415 (27) |
| Azathioprine | 54/655 (8) | Improvement | 147/415 (32) |
| (Hydroxy) chloroquine | 24/655 (4) | Stable disease | 100/415 (22) |
| Mycophenolate mofetil | 12/655 (2) | Deterioration | 19/415 (4) |
| Cyclosporine A | 10/655 (2) | Mortality | 42/826 (5) |
| Cyclophosphamide | 40/655 (6) | ||
| TNF-alpha antagonists | 24/655 (4) | Favourable outcome per treatment group | |
| Treatment switches | First line therapy | 161/227 (71) | |
| First to second or third line | 88/363 (24) | Second line therapy | 47/85 (55) |
| Second to third line | 14/104 (13) | Third line therapy | 7/18 (39) |
| Between third line | 7/23 (30) | ||
a n/N: number for which a certain characteristic is present out of the total number of patients for which it was described